Drug Profile


Alternative Names: ABT-333; Exviera; Viekira Pak (dasabuvir combination therapy); VIEKIRA XR

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Abbott Laboratories
  • Developer AbbVie
  • Class Antivirals; Naphthalenes; Pyrimidines; Small molecules; Sulfonamides
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatitis C

Most Recent Events

  • 01 Mar 2017 AbbVie completes the phase III ONYX-II trial in Hepatitis C (Combination therapy) in China, Taiwan, South Korea (PO) (NCT02517528)
  • 01 Mar 2017 AbbVie completes the phase III TURQUOISE-CPB trial in Hepatitis C (Combination therapy) in Germany, Canada and USA (NCT02219477)
  • 27 Feb 2017 CHMP of the EMA grants a positive opinion for the eight-week treatment option with ombitasvir/paritaprevir/ritonavir tablets in combination with dasabuvir tablets for Chronic hepatitis C virus infected genotype 1b (GT1b) patients with moderate fibrosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top